Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
$36.37
-0.7%
$39.20
$26.20
$63.50
$1.68B1.43727,808 shs516,518 shs
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$16.36
-2.9%
$18.73
$13.52
$35.25
$1.66B2.222.09 million shs1.90 million shs
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
$4.42
-8.1%
$3.96
$2.25
$8.08
$424.06M2.171.81 million shs1.55 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$26.97
+1.4%
$32.90
$24.28
$55.33
$1.63B2.361.19 million shs1.20 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
-3.10%+0.74%-3.45%-0.81%-24.39%
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-0.06%+5.25%-15.45%+7.05%-35.32%
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
+1.91%+11.60%+12.12%+16.18%-39.11%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-2.21%+0.45%-23.35%-9.93%-39.80%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
3.8703 of 5 stars
4.43.00.00.03.14.20.0
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
2.2467 of 5 stars
3.50.00.00.02.92.50.6
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
2.4101 of 5 stars
3.43.00.00.02.50.80.6
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.8397 of 5 stars
3.42.00.04.42.30.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
2.88
Moderate Buy$97.29169.53% Upside
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3.07
Buy$48.45195.94% Upside
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
2.86
Moderate Buy$16.29265.56% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.73
Moderate Buy$49.4085.57% Upside

Current Analyst Ratings Breakdown

Latest CMPS, APGE, BEAM, and TWST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/28/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/28/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$78.00 ➝ $87.00
8/14/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/11/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$90.00
8/6/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$25.00 ➝ $21.00
8/4/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/4/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$46.00
8/4/2025
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$45.00 ➝ $40.00
8/1/2025
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00
7/21/2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/15/2025
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$45.00
(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/AN/AN/AN/A$13.43 per shareN/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$60.27M27.48N/AN/A$10.35 per share1.58
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
N/AN/AN/AN/A$1.69 per shareN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$362.27M4.44N/AN/A$7.92 per share3.36
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
-$182.15M-$4.13N/AN/AN/AN/A-34.65%-32.76%11/11/2025 (Estimated)
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$376.74M-$4.50N/AN/AN/A-661.31%-43.15%-31.06%11/4/2025 (Estimated)
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
-$155.12M-$1.84N/AN/AN/AN/A-87.89%-57.77%10/30/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$1.45N/AN/AN/A-23.51%-29.03%-21.77%11/17/2025 (Estimated)

Latest CMPS, APGE, BEAM, and TWST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
-$1.03-$1.13-$0.10-$1.13N/AN/A
8/5/2025Q2 2025
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$1.04-$1.00+$0.04-$1.00$13.29 million$8.47 million
8/4/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54-$0.47+$0.07$0.33$95.52 million$96.06 million
7/31/2025Q2 2025
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
-$0.37-$0.38-$0.01-$0.41N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/AN/AN/AN/AN/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$0.905.50%N/AN/A N/A
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/A
16.36
16.36
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
N/A
6.75
6.75
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
0.16
8.82
8.82
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
3.90
3.60

Institutional Ownership

CompanyInstitutional Ownership
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
79.04%
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
99.68%
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
46.19%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
42.77%
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3.50%
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
3.93%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
9146.11 million26.39 millionOptionable
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
510101.16 million97.62 millionOptionable
COMPASS Pathways PLC Sponsored ADR stock logo
CMPS
COMPASS Pathways
12095.94 million92.17 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99060.36 million58.54 millionOptionable

Recent News About These Companies

Twist Bioscience (TWST) Receives a Buy from Guggenheim
Twist Bioscience Appoints Trynka Shineman Blake to Board
Twist Bioscience: Headwinds Are Mounting

New MarketBeat Followers Over Time

Media Sentiment Over Time

Apogee Therapeutics stock logo

Apogee Therapeutics NASDAQ:APGE

$36.37 -0.25 (-0.68%)
Closing price 04:00 PM Eastern
Extended Trading
$36.34 -0.02 (-0.07%)
As of 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Beam Therapeutics stock logo

Beam Therapeutics NASDAQ:BEAM

$16.36 -0.49 (-2.91%)
Closing price 04:00 PM Eastern
Extended Trading
$16.43 +0.07 (+0.40%)
As of 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

COMPASS Pathways stock logo

COMPASS Pathways NASDAQ:CMPS

$4.42 -0.39 (-8.11%)
Closing price 04:00 PM Eastern
Extended Trading
$4.49 +0.07 (+1.58%)
As of 05:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$26.97 +0.38 (+1.43%)
Closing price 04:00 PM Eastern
Extended Trading
$26.75 -0.22 (-0.82%)
As of 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.